Sarissa Capital, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger's ouster.
Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
In which Musk learns how to put a happy spin on failure from biotech CEOs.
Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.
The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
Will the biotech bubble support the comeback of Introgen Therapeutics, one of the sector's largest disasters?
Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.
Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.